SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lyka Labs gains on getting approval for selling manufacturing facilities in Maharashtra

15 Jul 2014 Evaluate

Lyka Labs has received an approval for sale of manufacturing facilities of formulations located at Tarapur in state of Maharashtra

Lyka Labs is currently trading at Rs. 15.40, up by 0.35 points or 2.33 % from its previous closing of Rs. 15.05 on the BSE.

The scrip opened at Rs. 15.10 and has touched a high and low of Rs. 15.65 and Rs. 15.10 respectively. So far 4731 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 21.70 on 13-Jun-2014 and a 52 week low of Rs. 8.46 on 07-Aug-2013.

Last one week high and low of the scrip stood at Rs. 18.40 and Rs. 15.00 respectively. The current market cap of the company is Rs. 33.23 crore.

The promoters holding in the company stood at 23.30 % while Institutions and Non-Institutions held 4.93 % and 71.78 % respectively.

Lyka Labs has received an approval for sale of manufacturing facilities of formulations located at Tarapur in state of Maharashtra. The board of directors at its meeting held on July 14, 2014 has approved for the same. The board also approved to seek approval of shareholders through Postal Ballot for sale of manufacturing facilities.

Lyka Labs is engaged in the manufacture of pharmaceutical products. It also manufactures Veterinary products including injections, powders, creams and suspensions. The company offers various surgical disposables, such as syringes, surgical blades, cotton crepe bandage and first aid kits.

Lyka Labs Share Price

58.80 -0.25 (-0.42%)
22-Apr-2026 09:58 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1660.45
Dr. Reddys Lab 1215.40
Cipla 1226.30
Zydus Lifesciences 928.40
Lupin 2300.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×